<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366653">
  <stage>Registered</stage>
  <submitdate>3/07/2014</submitdate>
  <approvaldate>21/07/2014</approvaldate>
  <actrnumber>ACTRN12614000781640</actrnumber>
  <trial_identification>
    <studytitle>A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects. 

</studytitle>
    <scientifictitle>A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Drug Description:
Dosage: 500 mg of ACT-451840 
Mode of Administration: Oral Suspension 
Frequency and Duration: Single dose

Strategies to monitor adherence: 
Oral suspension shall be administered in the presence of the investigational site team. 

Parasite introduction
Type of parasite/ dose: malaria inoculum of ~1,800 viable Plasmodium falciparum-infected human erythrocytes
Administration: Intravenously
Administration time: approximately 7 days prior to ACT-451840 administration. 

</interventions>
    <comparator>There is no control group. All subjects shall be administered with the malaria inoculum and all will receive ACT-451840 treatment. </comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To characterize the anti-malarial activity of ACT-451840 administered orally on clearance of Plasmodium falciparum blood stage parasites from the blood in healthy subjects.

Activities to be measured are antimalarial activity of ACT-451840 through bioassay; 
</outcome>
      <timepoint>up to 16 days after administration of ACT-451840. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To characterize the pharmacokinetics of ACT-451840 in the challenge model - introduction of Plasmodium falciparum blood stage parasites in healthy subjects.

Outcome shall be assessed pharmacokinetics sampling. </outcome>
      <timepoint>144 hours post dose
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the tolerability of ACT-451840 in the challenge model -  vital signs (temperature, heart rate, blood pressure and respiratory rate), hematology, biochemistry and liver functin test, urinalysis, adverse event monitoring.  </outcome>
      <timepoint>Up to 31 days after introduction of the Plasmodium falciparum blood stage parasites. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To investigate ex vivo / in vitro antimalarial activity of ACT-451840 (bioassay)</outcome>
      <timepoint>144 hours post dose
</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any history of malaria.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>6/06/2014</anticipatedstartdate>
    <actualstartdate>6/06/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>8</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Q-Pharm Pty Limited</hospital>
    <postcode>4006 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>James McCarthy </primarysponsorname>
    <primarysponsoraddress>Q-Pharm Pty Limited
Level 5, 300C Herston Road
Herston QLD 4006, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Actelion Pharmaceuticals Australia Pty.</fundingname>
      <fundingaddress>Suite 6
13B Narabang Way
Belrose NSW 2085</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Queensland Institute of Medical Research</ethicname>
      <ethicaddress>300 Herston Rd, Brisbane QLD 4006

</ethicaddress>
      <ethicapprovaldate>14/03/2014</ethicapprovaldate>
      <hrec>P2049</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>James McCarthy</name>
      <address>Q-Pharm Pty Limited
Level 5, 300C Herston Road,
Herston, QLD 4006</address>
      <phone>+61 07 3845 3636</phone>
      <fax />
      <email>j.mccarthy@uq.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>James McCarthy</name>
      <address>Q-Pharm Pty Limited
Level 5, 300C Herston Road,
Herston, QLD 4006</address>
      <phone>+61 07 3845 3636</phone>
      <fax />
      <email>j.mccarthy@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>James McCarthy</name>
      <address>Q-Pharm Pty Limited
Level 5, 300C Herston Road,
Herston, QLD 4006</address>
      <phone>+61 07 3845 3636</phone>
      <fax />
      <email>j.mccarthy@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Nathaniel L. Tolentino</name>
      <address>PAREXEL International
Suite B, Level 6
15 Talavera Road
North Ryde, NSW  Australia, 2113
</address>
      <phone>+61 02 8870 3730</phone>
      <fax />
      <email>Nathaniel.Tolentino@PAREXEL.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>